Gamma secretase inhibitors inhibit ovarian cancer development and enhance olaparib's anti-ovarian cancer activity and its mechanism
This study shows that gamma secretase inhibitors reduce ovarian cancer growth and boost olaparib's effectiveness by targeting the Notch/jagged1 and Wnt/beta-catenin pathways.